The research article presents a comprehensive evaluation of the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of disitamab vedotin (DV), a novel humanized anti-HER2 antibody-drug conjugate (ADC), for this rare adenocarcinoma.
Frontiers of MedicineSep 4 2024 The research article presents a comprehensive evaluation of the human epidermal growth factor receptor 2 status in extramammary Paget disease and explores the therapeutic potential of disitamab vedotin , a novel humanized anti-HER2 antibody-drug conjugate , for this rare adenocarcinoma.
HER2 overexpression or amplification is a known poor prognostic indicator in various malignancies and has been previously studied in EMPD, albeit with limited sample sizes. The rates of HER2 overexpression in EMPD have varied significantly across studies. The current research addresses this gap by conducting a retrospective study involving 129 EMPD cases from three medical centers, aiming to assess HER2 status through immunohistochemical staining and fluorescence in-situ hybridization analysis.
The study also reports on the use of DV in two patients with advanced EMPD who had previously failed to respond to chemotherapy. Both patients exhibited partial responses to DV treatment, as assessed using the modified RECIST 1.1 criteria. This finding suggests that even patients with low HER2 expression levels may benefit from HER2-targeted therapy, expanding the potential patient population for such treatments.
Antibody-Drug Conjugate Adenocarcinoma Chemotherapy Growth Factor Receptor Research Skin
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
UCLA team develops automated HER2 scoring system with deep learning and pyramid samplingHER2 is a critical protein that plays a pivotal role in breast cancer cell growth and aggressiveness. Its expression level is a key indicator for treatment decisions, including the use of HER2-targeted therapies.
Read more »
Decoding calcifications in breast cancer: Towards personalized medicineA recent study uncovers the molecular signatures of mammographic calcifications in hormone receptor-positive, HER2-negative breast cancer.
Read more »
Personalized treatment strategies based on calcification status in breast cancerMammographic calcifications, a common feature of breast cancer, have remained enigmatic in terms of their molecular underpinnings and clinical implications, particularly in the hormone receptor-positive, HER2-negative subtype.
Read more »
Novel molecular signaling pathway found to play a crucial role in maintaining the skin barrierOur skin–the body's largest organ–provides the first line of defense against infections and many other threats to our health.
Read more »
Novel vaccination strategy shows promise in boosting immunity and controlling influenza spread in pigsStudy demonstrates that a novel prime/boost vaccination protocol using live-attenuated influenza vaccines effectively induces strong immune responses in pigs, offering a promising approach for future influenza vaccination strategies.
Read more »
Study examines novel drug candidate for treatment of neuroHIVA recently published article in Experimental Biology and Medicine titled 'LM11A-31, a modulator of p75 neurotrophin receptor, suppresses HIV-1 replication and inflammatory response in macrophages' highlights the potential of a novel drug candidate, 2-amino-3-methylpentanoic acid [2-morpholin-4-yl-ethyl]-amide (LM11A-31),which is a p75...
Read more »